79324-77-9Relevant articles and documents
Synthesis of 3-bromo-5-(2-ethylimidazo[1, 2-a]pyridine-3-carbonyl)-2-hydroxybenzonitrile
-
Paragraph 0078-0080, (2020/07/24)
The invention discloses a synthetic method of 3-bromo-5-(2-ethylimidazo[1,2-a]pyridine-3-carbonyl)-2-hydroxybenzonitrile, particularly relates to a synthetic method of a compound shown as a formula (III), and particularly relates to a step A or a step B;
An investigation of structure‐activity relationships of azolylacryloyl derivatives yielded potent and long‐acting hemoglobin modulators for reversing erythrocyte sickling
Abdulmalik, Osheiza,El‐araby, Moustafa E.,Ghatge, Mohini S.,Muhammad, Yosra A.,Omar, Abdelsattar M.,Paredes, Steven D.,Safo, Martin K.
, p. 1 - 21 (2020/11/09)
Aromatic aldehydes that bind to sickle hemoglobin (HbS) to increase the protein oxygen affinity and/or directly inhibit HbS polymer formation to prevent the pathological hypoxia‐induced HbS polymerization and the subsequent erythrocyte sickling have for s
COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT
-
Paragraph 0092; 0093, (2018/08/01)
Provided are a compound as represented in formula (I), a pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and uses thereof. The compound as represented in formula (I) and the pharmaceutically acceptable salts thereof are used in the preparation of medicines for the treatment or prevention of hyperuricemia or gout by means of uric acid excretion.